

Pt	Age	Sex	Malignancy	ICI*	Time to onset (mo)	Mass effects	Pituitary hormone deficiencies
1	78	M	Melanoma	Ipilimumab → Pembrolizumab	2.6	Headache	ACTH**, TSH***
2	44	F	Melanoma	Ipilimumab	1.9	Headache	ACTH**, TSH***
3	48	F	Melanoma	Ipilimumab	2.2	Headache	ACTH**, Prolactin
4	67	M	Melanoma	Ipilimumab → Pembrolizumab	15.6	Absent	ACTH**, TSH***
5	56	M	Melanoma	Ipilimumab → Pembrolizumab	1.0	Headache	ACTH**, Gonadotropins
6	65	M	Melanoma	Ipilimumab → Pembrolizumab	11.1	Absent	ACTH**
7	65	M	Melanoma	Ipilimumab → Pembrolizumab	3.0	Absent	ACTH**, TSH***, Gonadotropins
8	60	M	Melanoma	Ipilimumab	1.5	Headache	ACTH**, TSH**
9	67	M	Head and neck	Pembrolizumab	5.1	Absent	ACTH**
10	57	M	Melanoma	Pembrolizumab	4.6	Absent	ACTH**, Gonadotropins
11	56	M	Melanoma	Ipilimumab → Pembrolizumab	2.8	Headache	ACTH**
12	47	F	Melanoma	Ipilimumab	2.9	Absent	ACTH**, Gonadotropins
13	71	M	Melanoma	Ipilimumab	2.7	Headache	ACTH**, TSH***
14	63	F	Breast	Pembrolizumab	3.4	Absent	ACTH**, TSH***
15	42	F	Melanoma	Pembrolizumab	8.9	Absent	ACTH**, TSH***
16	64	F	Melanoma	Ipilimumab and Nivolumab	2.1	Headache	ACTH**, TSH***, GH****
17	56	F	Melanoma	Ipilimumab	14.0	Absent	ACTH**
18	67	M	Melanoma	Pembrolizumab	7.9	Absent	ACTH**
19	58	F	Lung	Ipilimumab and Nivolumab	4.9	Headache	ACTH**
20	56	M	Melanoma	Ipilimumab	4.0	Absent	ACTH**
21	56	F	Melanoma	Ipilimumab → Pembrolizumab	17.7	Absent	ACTH**
22	56	F	Melanoma	Ipilimumab	2.9	Headache	ACTH**, TSH***, Prolactin
23	55	M	Melanoma	Pembrolizumab	1.3	Headache, visual deficit	ACTH**
24	57	F	Head and neck	Pembrolizumab f/b Ipilimumab	9.8	Absent	ACTH**
25	68	M	Melanoma	Pembrolizumab	1.2	Diplopia	ACTH**
26	67	F	Esophageal	Ipilimumab and Nivolumab	2.3	Headache, diplopia	ACTH**

Supplemental Table 1: Individual characteristics of ICI induced hypophysitis patients. *ICI: immune checkpoint inhibitor; **ACTH: adrenocorticotrophic hormone; ***TSH: thyroid stimulating hormone; ****GH: growth hormone